REGNCongressional Stock Trades
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
Congressional stock trades in Regeneron Pharmaceuticals Inc (REGN) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
14
Politicians Trading
9
Last Traded
Jul 7, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Julia LetlowR | Mar 12, 2026 | Feb 12, 2026 | Buy | $1,001 - $15,000 | +24.21% |
| Robert BresnahanR | Jun 9, 2025 | May 15, 2025 | Buy | $1,001 - $15,000 | +66.39% |
| Byron DonaldsR | May 24, 2025 | Apr 10, 2025 | Sell | $1,001 - $15,000 | +78.14% |
| Byron DonaldsR | May 24, 2025 | Apr 10, 2025 | Sell | $1,001 - $15,000 | +78.14% |
| Robert BresnahanR | May 8, 2025 | Apr 8, 2025 | Sell | $1,001 - $15,000 | +74.81% |
| Jefferson ShreveR | May 8, 2025 | Apr 7, 2025 | Sell | $15,001 - $50,000 | +69.94% |
| Robert BresnahanR | Mar 27, 2025 | Feb 25, 2025 | Sell | $1,001 - $15,000 | +34.54% |
Price History
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
9 members of Congress have disclosed 14 trades in Regeneron Pharmaceuticals Inc (REGN). Most active: Julie Johnson (3), Robert Bresnahan (3), Byron Donalds (2).
Across all disclosures, members of Congress reported 6 purchases and 8 sales of Regeneron Pharmaceuticals Inc (REGN). The most recent trade was on Jul 7, 2026.
Ro Khanna disclosed buying Regeneron Pharmaceuticals Inc (REGN) on Jul 7, 2026, valued at $1,001 - $15,000.
Byron Donalds disclosed selling Regeneron Pharmaceuticals Inc (REGN) on Apr 10, 2025, valued at $1,001 - $15,000.
From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.